First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study
Authors
Qiming Wang (ORCID: https://orcid.org/0000-0002-7813-2885)
Pingfei Wang
Baohui Han
Bo Zhang (ORCID: https://orcid.org/0000-0002-6902-9093)
Na Li (ORCID: https://orcid.org/0000-0002-4912-865X)
Xiaomei Liu (ORCID: https://orcid.org/0000-0003-3940-8049)
Fangling Ning (ORCID: https://orcid.org/0000-0002-6697-2262)
Wenxiu Yao (ORCID: https://orcid.org/0009-0008-0812-5656)
First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study
Qiming Wang, Pingfei Wang, Baohui Han, Bo Zhang et al.
Journal
Frontiers in Oncology
Topics
Lung Cancer Treatments and Mutations
article
First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study
Qiming Wang, Pingfei Wang, Baohui Han, Bo Zhang, Na Li, Xiaomei Liu, Fangling Ning, Wenxiu Yao, Hua Zhong
article en
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in OncologyVol. 15
Institutions
Binzhou Medical University (CN), University of Electronic Science and Technology of China (CN), Shandong University of Aeronautics (CN), Shanghai Chest Hospital (CN), Suizhou Central Hospital (CN), Sichuan Cancer Hospital (CN), Henan Cancer Hospital (CN), Dazhou Central Hospital (CN), Jinzhou Medical University (CN)